Clinical trials: Antibody
Solid Tumor, Adult
A Study of CS1002 in Subjects with Advanced Solid Tumors
This is a multicenter, open-label, multiple dose, dose escalation phase I study to evaluate the clinical safety, tolerability, PK, and preliminary anti-tumor efficacy of CS1002.
- Trial name
- NCT03523819
- Testing
- CS1002, CS1003
- Where
- 10 sites in Australia, Hong Kong
- Volunteers
- 91 people
- Sponsor
- CStone Pharmaceuticals
Intrahepatic Cholangiocarcinoma, Chemotherapy Effect
Low-dose Gemcitabine and Cisplatin and PD-1/PD-L1 Antibody Therapy in Intrahepatic Cholangiocarcinoma
In this phase 2 study, researchers aimed to evaluate the efficacy and safety of low-dose gemcitabine and cisplatin chemotherapy and the immune checkpoint inhibitor PD-1/PD-L1 antibody in patients with advanced and unresectable…
- Conditions
- Intrahepatic Cholangiocarcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- NCT06567600
- Testing
- Low-dose Gemcitabine and Cisplatin Chemotherapy plus PD-1/PD-L1Antibody
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Solid Tumor
A Study of of MORAb-004 in Subjects With Solid Tumors
The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.
- Trial name
- NCT00847054
- Testing
- MORAb-004 (monoclonal antibody to TEM1)
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- Morphotek
Kidney Transplantation
Impact of ExtraCorporeal Phototherapy (ECP) on Auxiliary Follicular T-lymphocytes and Circulating B-lymphocytes During Chronic AntiBody-Mediated Rejection in Kidney Transplantation.
Chronic AntiBody-Mediated Rejection (cABMR) is the leading cause of late kidney transplant loss (after 1 year of kidney transplantation).
- Trial name
- IPECAM (NCT04870437)
- Testing
- Extracorporeal phototherapy
- Where
- 4 sites in France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Angers
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Myasthenia Gravis Generalized
PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis
Myasthenia gravis (MG) is an autoimmune disease in which autoantibodies attack the neuromuscular junction, the site at which nerve cells communicate with muscle fibres, impairing signal transmission and causing fluctuating muscle…
- Trial name
- PANORAMA (NCT07717281)
- Where
- Italy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Non-Active Secondary Progressive Multiple Sclerosis
Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients
This is an open-label, intermediate-size patient population expanded access treatment study utilizing 1 dose level of nasal Foralumab (50 µg/dosing day) with the possibility of increasing to 100 µg/dosing day.
- Trial name
- NCT06802328
- Testing
- Foralumab TZLS-401 50 µg
- Where
- United States
- Sponsor
- Tiziana Life Sciences LTD
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Similarity of Pharmacokinetics and Safety
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
To evaluate the bioequivalence of HS627(2 specifications) with PERJETA in a single intravenous administration in healthy subjects
- Trial name
- NCT05323981
- Testing
- HS627(210mg/7ml), HS627(420mg/14ml), Perjeta
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
PD-1 Antibody, Mixed Chimerism
PD-1 Antibody Improve Mixed Chimerism
PD-1/PD-L1 pathway play an important role in Inhibiting the function of antigen-specific CD8+T cells, thus matter a lot in immune escape.
- Trial name
- HLH (NCT04944511)
- Testing
- Toripalimab Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Friendship Hospital
Solid Cancers
A Study of the Safety and Pharmacology of MetMAb (PRO143966), a Monovalent Antagonist Antibody to the Receptor C-Met, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors
This is a Phase I, open label, dose-escalation study of MetMAb administered by intravenous (IV) infusion in patients with advanced solid malignancies that are refractory to or for which there is no standard of care.
- Trial name
- NCT01068977
- Testing
- bevacizumab, MetMAb
- Volunteers
- 44 people
- Sponsor
- Genentech, Inc.
Breast Cancer
Chidamide Plus PD-1 Plus Paclitaxel of Neoadjuvant Treatment in Low HR Expression,HER2-negative Early Breast Cancer.
Triple-negative breast cancer has always been a difficult problem in clinical practice because of its young onset age, high aggressiveness, no clear therapeutic target and poor clinical prognosis.
- Trial name
- NCT05749575
- Testing
- Chidamide Plus Toripalimab Plus Paclitaxel
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Sun Yat-sen University
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05126719
- Testing
- MRG003, Capecitabine tablets, Docetaxel injection
- Where
- 23 sites in China
- Volunteers
- 238 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Auto-immune Encephalitis, Epilepsy
Antibodies Causing Epilepsy Syndromes: The ACES Study.
The Antibodies Causing Epilepsy Syndromes (ACES) Study is a observational cohort study focusing on detection of auto-immune epilepsy in patients with epilepsy of unknown origin.
- Trial name
- ACES (NCT02802475)
- Testing
- vena punction
- Where
- 8 sites in Netherlands
- Volunteers
- 582 people
- Sponsor
- Erasmus Medical Center
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Diffuse Large B-cell Lymphoma (DLBCL)
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy.
- Trial name
- OLYMPIA-3 (NCT06091865)
- Testing
- Odronextamab, Rituximab, Cyclophosphamide
- Where
- 195 sites in United States, Australia and 19 more
- Volunteers
- 904 people
- Sponsor
- Regeneron Pharmaceuticals
Kidney Transplant Rejection
Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients
This is a pilot study to determine if extended release Envarsus at an optimal level is just as effective as more invasive standard therapies for subclinical (mild) AMR (antibody mediated rejection) in kidney transplant patients.
- Trial name
- NCT03380936
- Testing
- Tacrolimus Extended Release Oral Tablet [Envarsus], Plasma Exchange and IVIG (Intravenous Immunoglobulin )
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Colorado, Denver
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy
For recurrent or persistent advanced cervical cancer patients, the first-line chemotherapy was based on platinum. However, if they were refractory to platinum-based chemotherapy, there were no other more effective medications or…
- Conditions
- Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemotherapy, Anti-PD-1 Antibody
- Trial name
- NCT04188860
- Testing
- A combination of anti-PD-1 antibody camrelizumab and albumin-bound paclitaxel
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Lei Li
Hepatocellular Carcinoma
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
The objective of this study is to evaluate the efficacy and safety of transcatheter arterial chemoembolization combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma as first line therapy.
- Trial name
- NCT04297280
- Testing
- Sintilimab, TACE
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Neuroblastoma
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and…
- Trial name
- NCT03363373
- Testing
- GM-CSF + Naxitamab
- Where
- 20 sites in United States, Canada and 7 more
- Volunteers
- 122 people
- Sponsor
- Y-mAbs Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.